George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
The partnership also immediately provides Avacta with additional manufacturing capacity through Mologic and its partners including Global Access Diagnostics (GAD), in addition to the scaled-up manufacturing capacity being built with BBI and Abingdon Health. Combined, these manufacturing partnerships will deliver several millions of tests per month, and potentially much higher with further investment. Avacta is also continuing its discussions with other manufacturers in the UK and overseas in order to access additional capacity to meet demand.
The partnership also immediately provides Avacta with additional manufacturing capacity through Mologic and its partners including Global Access Diagnostics (GAD), in addition to the scaled-up manufacturing capacity being built with BBI and Abingdon Health. Combined, these manufacturing partnerships will deliver several millions of tests per month, and potentially much higher with further investment. Avacta is also continuing its discussions with other manufacturers in the UK and overseas in order to access additional capacity to meet demand.
The partnership also immediately provides Avacta with additional manufacturing capacity through Mologic and its partners including Global Access Diagnostics (GAD), in addition to the scaled-up manufacturing capacity being built with BBI and Abingdon Health. Combined, these manufacturing partnerships will deliver several millions of tests per month, and potentially much higher with further investment. Avacta is also continuing its discussions with other manufacturers in the UK and overseas in order to access additional capacity to meet demand.
Nd71 stop the caution notes , we’ve crossed the line now , read the full accuracy of the huff post on Twitter Please , am still celebrating to worry about negativity now , my hope is Ben Harper is our pouncake / Arnold Palmer in disguise & is enjoying this brilliant moment in our lives , he deserves it after all the ramping he did :/)
Benjamin that’s a massive statement , looking at you’re previous statements your 50 /50 correct , but have to say your AML advice was spot on , can you go as far as saying , when you know it’s a our definite test , your’ll keep us informed :-)) , after all we all want retirement early as possible, good luck at your young tender age
Ohh , what a great joke, you made me smile with that one , let us all have big smiles , till our “ Martin Luther king “ I have a “ DREAM “comes true , with AVACTA , it’s only around the corner , more smiles , less growls investors , forget the pricks who continuously knock our product down, don’t invest in it if you don’t believe :-))
Does the RNS JUNE 13th 2016 still apply with mologic SAYS BOTH COMPANIES will share future revenues
Wetherby and Cambridge, UK, 13 June 2016: Avacta Group plc (AIM: AVCT) ("Avacta" or "the Group") the developer of Affimer® biotherapeutics and research reagents, and Mologic, a specialist diagnostic development company, today announced they have formed a collaborative partnership to develop diagnostic tests against multiple targets of clinical interest for point of care (POC) testing, using Avacta's Affimer technology. As stated at the time of Avacta's interim results, establishing commercial relationships in the POC testing market is one of the Company's key strategic objectives.
The non-exclusive collaboration with Mologic will focus on the development of novel Affimer-based diagnostic assays and the subsequent development of new lateral flow devices (LFDs) as POC diagnostics for human healthcare. Both companies will share in the future revenues from the commercialisation of the marketed diagnostics.
Perdita Barran
@PerditaB
·
4h
We, along with seven other universities,
@UniofNewcastle
@LivUni
@uniofleicester
@warwickuni
@UniofReading
@ucl
@unisouthampton
are running a rapid response pilot to determine the diagnostic and prognostic capabilities of mass spectrometry. 4/15